- Medicine (St Vincent's) - Research Publications
Medicine (St Vincent's) - Research Publications
Permanent URI for this collection
24 results
Filters
Reset filtersSettings
Statistics
Citations
Search Results
Now showing
1 - 10 of 24
-
ItemConsensus opinion from an international group of experts on measurable residual disease in hairy cell leukemiaRavandi, F ; Kreitman, RJ ; Tiacci, E ; Andritsos, L ; Banerji, V ; Barrientos, JC ; Bhat, SA ; Blachly, JS ; Broccoli, A ; Call, T ; Chihara, D ; Dearden, C ; Demeter, J ; Dietrich, S ; Else, M ; Epperla, N ; Falini, B ; Forconi, F ; Gladstone, DE ; Gozzetti, A ; Iyengar, S ; Johnston, JB ; Jorgensen, J ; Juliusson, G ; Lauria, F ; Lozanski, G ; Parikh, SA ; Park, JH ; Polliack, A ; Quest, G ; Robak, T ; Rogers, KA ; Saven, A ; Seymour, JF ; Tadmor, T ; Tallman, MS ; Tam, CS ; Thompson, PA ; Troussard, X ; Zent, CS ; Zenz, T ; Zinzani, PL ; Woermann, B ; Rai, K ; Grever, M (SPRINGERNATURE, 2022-12-13)A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent nature of the disease as well as reports suggesting long-term survival in patients treated with a single course of a nucleoside analog albeit without evidence of cure, the merits of detection of MRD and attempts to eradicate it have been debated. Studies utilizing novel strategies in the relapse setting have demonstrated the utility of achieving CR with undetectable MRD (uMRD) in prolonging the duration of remission. Several assays including immunohistochemical analysis of bone marrow specimens, multi-parameter flow cytometry and molecular assays to detect the mutant BRAF V600E gene or the consensus primer for the immunoglobulin heavy chain gene (IGH) rearrangement have been utilized with few comparative studies. Here we provide a consensus report on the available data, the potential merits of MRD assessment in the front-line and relapse settings and recommendations on future role of MRD assessment in HCL.
-
ItemNo Preview AvailableSingle-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapyThijssen, R ; Tian, L ; Anderson, MA ; Flensburg, C ; Jarratt, A ; Garnham, AL ; Jabbari, JS ; Peng, H ; Lew, TE ; Teh, CE ; Gouil, Q ; Georgiou, A ; Tan, T ; Djajawi, TM ; Tam, CS ; Seymour, JF ; Blombery, P ; Gray, DHD ; Majewski, IJ ; Ritchie, ME ; Roberts, AW ; Huang, DCS (AMER SOC HEMATOLOGY, 2022-11-17)Venetoclax (VEN) inhibits the prosurvival protein BCL2 to induce apoptosis and is a standard therapy for chronic lymphocytic leukemia (CLL), delivering high complete remission rates and prolonged progression-free survival in relapsed CLL but with eventual loss of efficacy. A spectrum of subclonal genetic changes associated with VEN resistance has now been described. To fully understand clinical resistance to VEN, we combined single-cell short- and long-read RNA-sequencing to reveal the previously unappreciated scale of genetic and epigenetic changes underpinning acquired VEN resistance. These appear to be multilayered. One layer comprises changes in the BCL2 family of apoptosis regulators, especially the prosurvival family members. This includes previously described mutations in BCL2 and amplification of the MCL1 gene but is heterogeneous across and within individual patient leukemias. Changes in the proapoptotic genes are notably uncommon, except for single cases with subclonal losses of BAX or NOXA. Much more prominent was universal MCL1 gene upregulation. This was driven by an overlying layer of emergent NF-κB (nuclear factor kappa B) activation, which persisted in circulating cells during VEN therapy. We discovered that MCL1 could be a direct transcriptional target of NF-κB. Both the switch to alternative prosurvival factors and NF-κB activation largely dissipate following VEN discontinuation. Our studies reveal the extent of plasticity of CLL cells in their ability to evade VEN-induced apoptosis. Importantly, these findings pinpoint new approaches to circumvent VEN resistance and provide a specific biological justification for the strategy of VEN discontinuation once a maximal response is achieved rather than maintaining long-term selective pressure with the drug.
-
ItemNo Preview AvailableRobust SARS-CoV-2 T cell responses with common TCRab motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cellsNguyen, THO ; Rowntree, LC ; Allen, LF ; Chua, BY ; Kedzierski, L ; Lim, C ; Lasica, M ; Tennakoon, GS ; Saunders, NR ; Crane, M ; Chee, L ; Seymour, JF ; Anderson, MA ; Whitechurch, A ; Clemens, EB ; Zhang, W ; Chang, SY ; Habel, JR ; Jia, X ; McQuilten, HA ; Minervina, AA ; Pogorelyy, MV ; Chaurasia, P ; Petersen, J ; Menon, T ; Hensen, L ; Neil, JA ; Mordant, FL ; Tan, H-X ; Cabug, AF ; Wheatley, AK ; Kent, SJ ; Subbarao, K ; Karapanagiotidis, T ; Huang, H ; Vo, LK ; Cain, NL ; Nicholson, S ; Krammer, F ; Gibney, G ; James, F ; Trevillyan, JM ; Trubiano, JA ; Mitchell, J ; Christensen, B ; Bond, KA ; Williamson, DA ; Rossjohn, J ; Crawford, JC ; Thomas, PG ; Thursky, KA ; Slavin, MA ; Tam, CS ; Teh, BW ; Kedzierska, K (CELL PRESS, 2023-04-18)Immunocompromised hematology patients are vulnerable to severe COVID-19 and respond poorly to vaccination. Relative deficits in immunity are, however, unclear, especially after 3 vaccine doses. We evaluated immune responses in hematology patients across three COVID-19 vaccination doses. Seropositivity was low after a first dose of BNT162b2 and ChAdOx1 (∼26%), increased to 59%-75% after a second dose, and increased to 85% after a third dose. While prototypical antibody-secreting cells (ASCs) and T follicular helper (Tfh) cell responses were elicited in healthy participants, hematology patients showed prolonged ASCs and skewed Tfh2/17 responses. Importantly, vaccine-induced expansions of spike-specific and peptide-HLA tetramer-specific CD4+/CD8+ T cells, together with their T cell receptor (TCR) repertoires, were robust in hematology patients, irrespective of B cell numbers, and comparable to healthy participants. Vaccinated patients with breakthrough infections developed higher antibody responses, while T cell responses were comparable to healthy groups. COVID-19 vaccination induces robust T cell immunity in hematology patients of varying diseases and treatments irrespective of B cell numbers and antibody response.
-
ItemDevelopment of a distributed international patient data registry for hairy cell leukemiaAndritsos, LA ; Anghelina, M ; Neal, J ; Blachly, JS ; Mathur, P ; Lele, O ; Dearden, C ; Iyengar, S ; Cross, M ; Zent, CS ; Rogers, KA ; Epperla, N ; Lozanski, G ; Oakes, CC ; Kraut, E ; Ruppert, AS ; Zhao, Q ; Bhat, SA ; Forconi, F ; Banerji, V ; Handunnetti, S ; Tam, CS ; Seymour, JF ; Else, M ; Kreitman, RJ ; Saven, A ; Call, T ; Parikh, SA ; Ravandi, F ; Johnston, JB ; Tiacci, E ; Troussard, X ; Tallman, MS ; Dietrich, S ; Tadmor, T ; Gozzetti, A ; Zinzani, PL ; Robak, T ; Quest, G ; Demeter, J ; Rai, K ; Fernandez, SA ; Grever, M (TAYLOR & FRANCIS LTD, 2022-11-10)Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder, comprising only 2% of all leukemias. The Hairy Cell Leukemia Foundation (HCLF) has developed a patient data registry to enable investigators to better study the clinical features, treatment outcomes, and complications of patients with HCL. This system utilizes a centralized registry architecture. Patients are enrolled at HCL Centers of Excellence (COE) or via a web-based portal. All data are de-identified, which reduces regulatory burden and increases opportunities for data access and re-use. To date, 579 patients have been enrolled in the registry. Efforts are underway to engage additional COE's to expand access to patients across the globe. This international PDR will enable researchers to study outcomes in HCL in ways not previously possible due to the rarity of the disease and will serve as a platform for future prospective research.
-
ItemEnrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistanceBlombery, P ; Thompson, ER ; Lew, TE ; Tiong, IS ; Bennett, R ; Cheah, CY ; Lewis, KL ; Handunnetti, SM ; Tang, CPS ; Roberts, A ; Seymour, JF ; Tam, CS (ELSEVIER, 2022-10-25)The covalent Bruton's tyrosine kinase inhibitors (BTKis) are highly effective for the treatment of chronic lymphocytic leukemia (CLL). The dominant resistance mechanism observed with the BTKi ibrutinib is the development of BTK Cys481 codon mutations. Whether a similar resistance mutation profile exists for the newer-generation, more selective BTKi zanubrutinib is unknown. In samples referred for diagnostic next-generation sequencing in patients with progressive CLL, we observed an enrichment in the kinase-dead BTK Leu528Trp mutation in patients treated with zanubrutinib compared with ibrutinib (54%; 7 of 13 vs 4%; 1 of 24, P = .001). We describe 2 patients with BTK Leu528Trp mutations who showed clinical cross-resistance and progressive enrichment of the BTK Leu528Trp mutation over time when treated with the noncovalent BTKi pirtobrutinib. Both patients subsequently responded to venetoclax-based treatment. In summary, we have identified an enrichment of the BTK Leu528Trp mutation arising in patients treated with zanubrutinib that may impart cross-resistance to the noncovalent inhibitor pirtobrutinib and therefore may have implications for sequencing of these treatments in CLL.
-
ItemSingle-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitorsThompson, ER ; Nguyen, T ; Kankanige, Y ; Markham, JF ; Anderson, MA ; Handunnetti, SM ; Thijssen, R ; Yeh, PS-H ; Tam, CS ; Seymour, JF ; Roberts, AW ; Westerman, DA ; Blombery, P (ELSEVIER, 2022-01-25)The genomic landscape of resistance to targeted agents (TAs) used as monotherapy in chronic lymphocytic leukemia (CLL) is complex and often heterogeneous at the patient level. To gain insight into the clonal architecture of acquired genomic resistance to Bruton tyrosine kinase (BTK) inhibitors and B-cell lymphoma 2 (BCL2) inhibitors in CLL, particularly in patients carrying multiple resistance mutations, we performed targeted single-cell DNA sequencing of 8 patients who developed progressive disease (PD) on TAs (either class). In all cases, analysis of single-cell architecture revealed mutual exclusivity between multiple resistance mutations to the same TA class, variable clonal co-occurrence of multiple mutations affecting different TAs in patients exposed to both classes, and a phenomenon of multiple independent emergences of identical nucleotide changes leading to canonical resistance mutations. We also report the first observation of established BCL2 resistance mutations in a patient with mantle cell lymphoma (MCL) following PD on sequential monotherapy, implicating BCL2 as a venetoclax resistance mechanism in MCL. Taken together, these data reveal the significant clonal complexity of CLL and MCL progression on TAs at the nucleotide level and confirm the presence of multiple, clonally independent, mechanisms of TA resistance within each individual disease context.
-
ItemTargeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin LymphomasMinson, A ; Tam, C ; Dickinson, M ; Seymour, JF (MDPI, 2022-03)Targeted therapies continue to change the landscape of lymphoma treatment, resulting in improved therapy options and patient outcomes. Numerous agents are now approved for use in the indolent lymphomas and many others under development demonstrate significant promise. In this article, we review the landscape of targeted agents that apply to the indolent lymphomas, predominantly follicular lymphoma, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia and marginal zone lymphoma. The review covers small molecule inhibitors, immunomodulators and targeted immunotherapies, as well as presenting emerging and promising combination therapies.
-
ItemHigh-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphomaCheah, CY ; Joske, D ; Cull, G ; Gilbertson, M ; Opat, SS ; Tam, CS ; Wirth, A ; Seymour, JF (WILEY, 2017-09)
-
ItemPlasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitorsChan, K-L ; Blombery, P ; Jones, K ; Lade, S ; Carney, D ; Tran, H ; Seymour, JF ; Tam, CS (WILEY, 2017-04)
-
ItemIbrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemiaTam, CS ; Kimber, T ; Seymour, JF (WILEY, 2017-03)
- «
- 1 (current)
- 2
- 3
- »